Contineum Therapeutics, Inc. (CTNM) Misses Q2 EPS by 34c

Contineum Therapeutics, Inc. (NASDAQ: CTNM) reported Q2 EPS of ($0.62), $0.34 worse than the analyst estimate of ($0.28).

For earnings history and earnings-related data on Contineum Therapeutics, Inc. (CTNM) click here.

You May Also Be Interested In

• After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
• The Gap, Inc. (GAP) Tops Q2 EPS by 3c
• Deutsche Bank Starts Rhythm Pharmaceuticals (RYTM) at Hold